Previous 10 | Next 10 |
2023-10-05 16:56:44 ET More on Cellectar Biosciences Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for Cellectar Biosciences For further details see: Cellectar Bioscie...
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to ...
FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines...
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on ...
2023-09-06 08:31:02 ET Verb Technology Company ( VERB ) -27% . Digital Brands Group ( DBGI ) -14% . GD Culture Group Limited ( GDC ) -12% . EZGO Technologies ( EZGO ) -10% . Photronics ( PLAB ) -9% after Q3 earning release . ...
2023-09-05 13:07:33 ET Gainers: Helius Medical Technologies ( HSDT ) +a55% . Novo Integrated Sciences ( NVOS ) +38% . Shengfeng Development Limited ( SFWL ) +29% . Cibus ( CBUS ) +28% . Cellectar Biosciences ( CLRB ) +28% . C...
2023-09-05 12:14:58 ET Cellectar Biosciences ( NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company, Tuesday said it has entered into a securities purchase agreement with certain institutional investors for a private placement financing that is expected to result in gro...
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is one today's most active stocks by volume. So far today, approximately 29.61M shares of Cellectar Biosciences, Inc. have been exchanged, as compared to an average 30-day volume of 17,273 shares. Cellectar Biosciences, Inc., a clinical biopharmaceuti...
2023-09-05 10:00:14 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 F...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...